| scholarly article | Q13442814 |
| P50 | author | Shayan Cheraghlou | Q88658348 |
| P2093 | author name string | Young Lim | |
| Keith Choate | |||
| P2860 | cites work | Hypoxia, hormones, and endothelial progenitor cells in hemangioma | Q24314928 |
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
| Evidence by molecular profiling for a placental origin of infantile hemangioma | Q24535837 | ||
| A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites | Q24603988 | ||
| Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi | Q24646052 | ||
| Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies | Q26866482 | ||
| Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects | Q27333126 | ||
| IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives | Q28066926 | ||
| GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas | Q28144358 | ||
| The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 | Q28204439 | ||
| Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma | Q28216461 | ||
| Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma | Q28256077 | ||
| Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA | Q28256964 | ||
| Somatic Activating PIK3CA Mutations Cause Venous Malformation | Q28270654 | ||
| Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ | Q28290315 | ||
| The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene | Q28293738 | ||
| IDH mutation impairs histone demethylation and results in a block to cell differentiation | Q29305058 | ||
| ras oncogenes in human cancer: a review | Q29547769 | ||
| Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation | Q29615366 | ||
| IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype | Q29617457 | ||
| Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha | Q29619709 | ||
| Symptomatic Congenital Hemangioma and Congenital Hemangiomatosis Associated With a Somatic Activating Mutation in GNA11. | Q33434036 | ||
| Sirolimus in the Treatment of Vascular Anomalies | Q33435894 | ||
| A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma. | Q33756156 | ||
| Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma | Q33874474 | ||
| Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma | Q33945917 | ||
| Enchondromatosis: insights on the different subtypes. | Q34007437 | ||
| Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma | Q34212750 | ||
| Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics | Q34277771 | ||
| Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin | Q34333539 | ||
| PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities | Q34376048 | ||
| Mammalian G proteins and their cell type specific functions | Q34453802 | ||
| ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features | Q34501081 | ||
| A randomized, controlled trial of oral propranolol in infantile hemangioma. | Q34668015 | ||
| Hemangioma in twins. | Q50964411 | ||
| Activation of Ras-dependent signaling pathways by G(14) -coupled receptors requires the adaptor protein TPR1. | Q53161914 | ||
| Translocation t(7;19)(q22;q13)−a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma? | Q54375142 | ||
| Candidate locus analysis for PHACE syndrome. | Q55093523 | ||
| R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations | Q57741090 | ||
| Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy | Q58081557 | ||
| Sirolimus for the treatment of complicated vascular anomalies in children | Q59763443 | ||
| A novelSERPINE1-FOSBfusion gene results in transcriptional up-regulation ofFOSBin pseudomyogenic haemangioendothelioma | Q60727776 | ||
| Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML | Q63170614 | ||
| Genetic mapping of a novel familial form of infantile hemangioma | Q77899982 | ||
| Recurrent GNA14 mutations in anastomosing haemangiomas | Q88161588 | ||
| Single-nucleotide polymorphisms of VEGF-A and VEGFR-2 genes and risk of infantile hemangioma | Q89469600 | ||
| Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma | Q34687930 | ||
| Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells. | Q34734440 | ||
| Somatic Activating RAS Mutations Cause Vascular Tumors Including Pyogenic Granuloma. | Q35602481 | ||
| Sirolimus for the treatment of children with various complicated vascular anomalies. | Q35651949 | ||
| Clonality and altered behavior of endothelial cells from hemangiomas. | Q36163041 | ||
| Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome | Q36190010 | ||
| Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins | Q36267106 | ||
| Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies | Q36518788 | ||
| Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma | Q36802954 | ||
| Pathogenesis of infantile haemangioma. | Q37001304 | ||
| The placenta theory and the origin of infantile hemangioma | Q37120899 | ||
| GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation | Q37153016 | ||
| Endothelial Cells from Capillary Malformations Are Enriched for Somatic GNAQ Mutations | Q37591818 | ||
| Copy number variation analysis in 98 individuals with PHACE syndrome | Q37677825 | ||
| LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies | Q37769610 | ||
| Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis | Q37918106 | ||
| Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis | Q38059089 | ||
| Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling | Q38356040 | ||
| Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations | Q38389849 | ||
| JAGGED1 signaling regulates hemangioma stem cell-to-pericyte/vascular smooth muscle cell differentiation | Q38461904 | ||
| Hypothesis: the metastatic niche theory can elucidate infantile hemangioma development | Q38540486 | ||
| Inheritance Patterns of Infantile Hemangioma | Q39111343 | ||
| Distribution of plasminogen activator inhibitor (PAI-1) in tissues | Q39463162 | ||
| BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma | Q40070685 | ||
| Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation | Q40443186 | ||
| Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia | Q41530079 | ||
| Pericytes from infantile hemangioma display proangiogenic properties and dysregulated angiopoietin-1 | Q42238341 | ||
| A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. | Q43602972 | ||
| Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations. | Q45138923 | ||
| Treatment of pediatric pyogenic granulomas using β-adrenergic receptor antagonists. | Q45996317 | ||
| Twenty years' experience of steroids in infantile hemangioma--a developing country's perspective | Q46053628 | ||
| A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature | Q46093683 | ||
| The somatic GNAQ mutation c.548G>A (p.R183Q) is consistently found in Sturge-Weber syndrome | Q48464435 | ||
| A vaccine targeting mutant IDH1 induces antitumour immunity | Q48649314 | ||
| Blue rubber bleb nevus syndrome: successful treatment with sirolimus | Q50250804 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 590 | |
| P577 | publication date | 2019-04-30 | |
| P1433 | published in | F1000Research | Q27701587 |
| P1476 | title | Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention | |
| P478 | volume | 8 |
Search more.